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The BB2 receptor, belonging to the Bombesin receptor family, has been shown to 
be highly over expressed in a variety of cancer cell lines, including human prostate 
cancer. Our laboratory have been involved, for over a decade, in synthesizing 
Bombesin analogues that target the BB2 receptor for the purpose of developing 
radiopharmaceuticals for diagnostic and/or therapeutic treatment of cancer. 
Radiopharmaceuticals based on Bombesin are typically composed of a chelator, 
isotope, linking group and targeting vector [See Bifunctional Conjugate Design 
[figure below]. Previous studies by our group and others have shown that variations 
in linking groups affect the retention time of the bifunctional conjugate in prostate 
cancer (PC-3) cells. Higher retention time allows for more efficacious therapeutic 
benefits and enhanced diagnostic imaging capabilities. In this study, we seek to 
determine the pharmacokinetic benefits achieved in altering the linking group using 
aliphatic and aromatic linking groups. In-vitro analysis of the radiopharmaceuticals 
studied found that the Bombesin derivative with the aliphatic linking group 
demonstrated a slightly higher affinity for the BB2 receptor compared to the 
Bombesin analogs containing aromatic linking groups. In vivo pharmacokinetic and 
imaging studies were performed using pre-clinical models of prostate cancer. The 
tumor uptake of the Bombesin derivatives with the aromatic linking groups were 
found to be significantly higher compared to that of the Bombesin derivative with 
the aliphatic linking group. In contrast, the aromatic Bombesin analogs also 
exhibited higher amounts of undesirable accumulation in the kidneys and other 
non-target tissues. In conclusion, we found that the aliphatic compounds were 
more appropriate for diagnostic imaging of prostate cancer due to the reduced non-
target retention. The Bombesin analogs with aromatic linking groups showed 
potential for use as therapeutic agents for prostate cancer treatment. 
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